The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
AC Immune-Janssen Partnered Alzheimer’s Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial
AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety And Potent Immunogenicity Of pTau Alzheimer’s Vaccine In High-dose Cohort
AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced new interim 10-week data from the high-dose cohort of a
SVB Leerink Maintains Outperform on AC Immune, Lowers Price Target to $15
SVB Leerink analyst Marc Goodman maintains AC Immune (NASDAQ:ACIU) with a Outperform and lowers the price target from $17 to $15.
AC Immune Announces Interim Phase 1b/2a Data Showing That Its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates A ‘Potent Immune Response’
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment
New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development
76 Biggest Movers From Yesterday
Gainers
Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.
AC Immune Announces Late-Breaker Presentation By Genentech At CTAD On Phase 2 Lauriet Study Of Semorinemab In Mild-To-Moderate Alzheimer’s Disease
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, presented the full topline